explore -WSS

explore

author：entertainment 2025-09-28 02:28:37 - browse：9389

Adam's take main illustration — Molly Ferguson/STAT

This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

The next ALS data readout — overdue but important

A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Top private equity targets in 2023: cardiology, clinical trials, lasers

focus

leisure time

WSS

Listen: Your guide to Wegovy's blockbuster heart study

What’s missing from the debate over nursing home staff minimums

Top private equity targets in 2023: cardiology, clinical trials, lasers

Global cancer cases to surge 77% by 2050, WHO report says

AstraZeneca stays mum on Medicare drug pricing negotiations

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

knowledge

explore

The next ALS data readout — overdue but important

Wikipedia

What does generative AI mean for health care? We asked experts

Medicare Advantage plans can’t deny care with AI, CMS warns

Peter Hotez and the public health issue of online harassment

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Guidelines to prevent youth baseball injuries need more muscle

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

The cancer drug shortage isn’t new — and neither are the solutions

Global cancer cases to surge 77% by 2050, WHO report says

Trump demands the U.S. pay no more for drugs than other countries … again

Devoted Health’s losses in Medicare Advantage persist

focus

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

Who are the detained American citizens released from prison in Iran?

Adopting new red light myopia treatments may be short

Listen: Your guide to Wegovy's blockbuster heart study

Medicare Advantage plans can’t deny care with AI, CMS warns

focus

leisure time

leisure time

hotspot